Andreas Kogelnik

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source: www.openmedicinefoundation.org

Andreas M. Kogelnik, ("Andy") MD, PhD., is an Internal Medicine and Infectious Diseases specialist, the director of the Open Medicine Institute, Mountain View, California, USA, and a member of the Scientific Advisory Board for the Open Medicine Foundation, Agoura Hills, CA.[1][2] His interests are in the bioinformatics and genomic revolution in medicine and is committed to the study of and treatment of ME/CFS and other chronic illnesses.[3][4]

Education[edit]

  • MD from Emory University
  • PhD in bioengineering from Georgia Tech
  • Residency in Internal Medicine at Stanford University
  • Fellowship in Infectious Diseases at Stanford University

Research publications on ME/CFS[edit]

  • 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study
    "Abstract - In the Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we relied on expert clinician diagnoses to enroll patients from 7 specialty clinics in the United States in order to perform a systematic collection of data on measures of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Healthy persons and those with other illnesses that share some features with ME/CFS were enrolled in comparison groups. The major objectives were to: 1) use standardized questionnaires to measure illness domains of ME/CFS and to evaluate patient heterogeneity overall and between clinics; 2) describe the course of illness, identify the measures that best correlate with meaningful clinical differences, and assess the performances of questionnaires as patient/person-reported outcome measures; 3) describe prescribed medications, orders for laboratory and other tests, and management tools used by expert clinicians to care for persons with ME/CFS; 4) collect biospecimens for future hypothesis testing and for evaluation of morning cortisol profiles; and 5) identify measures that best distinguish persons with ME/CFS from those in the comparison groups and detect subgroups of persons with ME/CFS who may have different underlying causes. Enrollment began in 2012 and is planned to continue in multiple stages through 2017. We present the MCAM methods in detail, along with an initial description of the 471 patients with ME/CFS who were enrolled in stage 1."[5]
  • 2013, Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.[6]
  • 2011, No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected.[7]
  • 2006, Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.[8]

Articles[edit]

Talks and Interviews[edit]

References[edit]

  1. http://www.openmedicineinstitute.org/the-clinic.html
  2. http://www.openmedicinefoundation.org/scientific-advisory-board/
  3. http://www.openmedicineinstitute.org/the-clinic.html
  4. http://www.openmedicinefoundation.org/scientific-advisory-board/
  5. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029 
  6. Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, Watt T, Kubo JT, Paik J, Desai M.(2013). Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. Journal of Medical Virology,85 (12):2101-9. doi: 10.1002/jmv.23713. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23959519
  7. Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, Hackett J Jr, Qiu X, Luk KC, Schochetman G, Knox A, Kogelnik AM, Levy JA.(2011). No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science,333 (6038):94-7. doi: 10.1126/science.1204963. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21628393
  8. Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. Journal of Clinical Virology,37 Suppl 1:S33-8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed /17276366


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history